Last updated
Lonza: Partnership
Lonza (leading CDMO) and Engitix (ECM-based drug discovery specialist) announced licensing agreement to advance antibody-drug conjugate (ADC) development for chronic disease therapies.
Source: GNW — United Kingdom
The leadership read
Alliances broaden the commercial surface, and the leadership need follows. Lonza's partnership in the sector widens demand for commercial and alliance leaders who turn an agreement into realised value. Across EMEA, watch whether dedicated senior ownership is put on it; unowned alliances quietly lapse.
Market context: The wider read — a Talent Market Index of 104.6 (Hot), down 1.9 month-on-month — shows EMEA signal flow easing (-2.2pts).
Lonza: 2 signals in the last 90 days; 0.1% of MitchelLake's EMEA signal flow; 3 tracked across 76 days.
Also at Lonza →
More signals across EMEA
Partnership · EMEA
Orange →Orange and Morrison infrastructure investor announced a 50/50 joint venture to build a data center company in France with €3 billion investment targeting 400 MW capacity (10x Orange's current capacity)
Partnership · EMEA
Revolut →Revolut partnered with OpenAI to offer retail customers up to one year of free ChatGPT Go access
Partnership · EMEA
AG1 →AG1 (gut health/wellness brand) announced its first football sponsorship deal as front-of-shirt sponsor for Swansea City FC. The partnership marks AG1's entry into professional football and comes as the brand has existing relationships with athletes including Lewis Hamilton, Hugh Jackman, and Allyson Felix.
Partnership · EMEA
Brillio →Brillio designated as OpenAI Select Partner to help enterprises implement AI at scale, combining OpenAI's AI capabilities with Brillio's engineering-oriented approach
Partnership · EMEA
Specsavers →Specsavers partnered with darts champion Beau Greaves to insure her eyes for £1m, leveraging her profile to promote vision health and position the brand in the growing sports sponsorship ecosystem in darts.
Partnership · EMEA
10x Genomics →10x Genomics announced multi-year research collaboration with Lausanne University Hospital (CHUV) on 29 July 2026 to study tumor samples from advanced cancer patients using Flex, Xenium and planned Atera platforms for oncology biomarker discovery.
Intelligence powered by Autonodal ↗